Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.

Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-Joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P.

Cancer Immunol Immunother. 2019 Mar;68(3):379-393. doi: 10.1007/s00262-018-2283-0. Epub 2018 Dec 13.

PMID:
30547218
2.

The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.

Villanueva L, Silva L, Llopiz D, Ruiz M, Iglesias T, Lozano T, Casares N, Hervas-Stubbs S, Rodríguez MJ, Carrascosa JL, Lasarte JJ, Sarobe P.

Oncoimmunology. 2017 Dec 21;7(4):e1409321. doi: 10.1080/2162402X.2017.1409321. eCollection 2018.

3.

Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice.

Lasarte-Cia A, Lozano T, Pérez-González M, Gorraiz M, Iribarren K, Hervás-Stubbs S, Sarobe P, Rabal O, Cuadrado-Tejedor M, García-Osta A, Casares N, Lasarte JJ.

Front Immunol. 2018 Jan 25;9:68. doi: 10.3389/fimmu.2018.00068. eCollection 2018.

4.

Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.

Celay J, Lozano T, Concepcion AR, Beltrán E, Rudilla F, García-Barchino MJ, Robles EF, Rabal O, de Miguel I, Panizo C, Casares N, Oyarzabal J, Prieto J, Medina JF, Lasarte JJ, Martínez-Climent JÁ.

Haematologica. 2018 Jun;103(6):1065-1072. doi: 10.3324/haematol.2017.175687. Epub 2017 Nov 30.

5.

Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.

Lozano T, Gorraiz M, Lasarte-Cía A, Ruiz M, Rabal O, Oyarzabal J, Hervás-Stubbs S, Llopiz D, Sarobe P, Prieto J, Casares N, Lasarte JJ.

Oncotarget. 2017 May 13;8(42):71709-71724. doi: 10.18632/oncotarget.17845. eCollection 2017 Sep 22.

6.

Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA).

Soldevilla MM, Hervas S, Villanueva H, Lozano T, Rabal O, Oyarzabal J, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F.

PLoS One. 2017 Sep 21;12(9):e0185169. doi: 10.1371/journal.pone.0185169. eCollection 2017.

7.

Therapeutic blockade of Foxp3 in experimental breast cancer models.

Moreno Ayala MA, Gottardo MF, Imsen M, Asad AS, Bal de Kier Joffé E, Casares N, Lasarte JJ, Seilicovich A, Candolfi M.

Breast Cancer Res Treat. 2017 Nov;166(2):393-405. doi: 10.1007/s10549-017-4414-2. Epub 2017 Jul 29.

PMID:
28756536
8.

Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance.

Consuegra-Fernández M, Martínez-Florensa M, Aranda F, de Salort J, Armiger-Borràs N, Lozano T, Casares N, Lasarte JJ, Engel P, Lozano F.

Front Immunol. 2017 May 30;8:594. doi: 10.3389/fimmu.2017.00594. eCollection 2017.

9.

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies.

San José-Enériz E, Agirre X, Rabal O, Vilas-Zornoza A, Sanchez-Arias JA, Miranda E, Ugarte A, Roa S, Paiva B, Estella-Hermoso de Mendoza A, Alvarez RM, Casares N, Segura V, Martín-Subero JI, Ogi FX, Soule P, Santiveri CM, Campos-Olivas R, Castellano G, de Barrena MGF, Rodriguez-Madoz JR, García-Barchino MJ, Lasarte JJ, Avila MA, Martinez-Climent JA, Oyarzabal J, Prosper F.

Nat Commun. 2017 May 26;8:15424. doi: 10.1038/ncomms15424.

10.

Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

Fernandez-Poma SM, Salas-Benito D, Lozano T, Casares N, Riezu-Boj JI, Mancheño U, Elizalde E, Alignani D, Zubeldia N, Otano I, Conde E, Sarobe P, Lasarte JJ, Hervas-Stubbs S.

Cancer Res. 2017 Jul 1;77(13):3672-3684. doi: 10.1158/0008-5472.CAN-17-0236. Epub 2017 May 18.

11.

A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis.

Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, Bértolo C, Lasarte JJ, Vicent S, Hoehlig K, Vater A, Lecanda F, Montuenga LM, Pio R.

Cancer Discov. 2017 Jul;7(7):694-703. doi: 10.1158/2159-8290.CD-16-1184. Epub 2017 Mar 13.

12.

Reversal of Diabetes in NOD Mice by Clinical-Grade Proinsulin and IL-10-Secreting Lactococcus lactis in Combination With Low-Dose Anti-CD3 Depends on the Induction of Foxp3-Positive T Cells.

Takiishi T, Cook DP, Korf H, Sebastiani G, Mancarella F, Cunha JP, Wasserfall C, Casares N, Lasarte JJ, Steidler L, Rottiers P, Dotta F, Gysemans C, Mathieu C.

Diabetes. 2017 Feb;66(2):448-459. doi: 10.2337/db15-1625. Epub 2016 Nov 8.

13.

IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.

Llopiz D, Ruiz M, Infante S, Villanueva L, Silva L, Hervas-Stubbs S, Alignani D, Guruceaga E, Lasarte JJ, Sarobe P.

Oncotarget. 2017 Jan 10;8(2):2659-2671. doi: 10.18632/oncotarget.13736.

14.

Evaluation of a Salmonella Strain Lacking the Secondary Messenger C-di-GMP and RpoS as a Live Oral Vaccine.

Latasa C, Echeverz M, García B, Gil C, García-Ona E, Burgui S, Casares N, Hervás-Stubbs S, Lasarte JJ, Lasa I, Solano C.

PLoS One. 2016 Aug 18;11(8):e0161216. doi: 10.1371/journal.pone.0161216. eCollection 2016.

15.

T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates.

Rollier CS, Verschoor EJ, Verstrepen BE, Drexhage JA, Paranhos-Baccala G, Liljeström P, Sutter G, Arribillaga L, Lasarte JJ, Bartosch B, Cosset FL, Inchauspe G, Heeney JL.

Gene Ther. 2016 Oct;23(10):753-759. doi: 10.1038/gt.2016.55. Epub 2016 Jul 14.

PMID:
27416077
16.

Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop.

Berraondo P, Ochoa MC, Rodriguez-Ruiz ME, Minute L, Lasarte JJ, Melero I.

Cancer Res. 2016 May 15;76(10):2863-7. doi: 10.1158/0008-5472.CAN-15-3279. Epub 2016 May 2.

17.

Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination.

Llopiz D, Aranda F, Díaz-Valdés N, Ruiz M, Infante S, Belsúe V, Lasarte JJ, Sarobe P.

Oncoimmunology. 2015 Aug 12;5(2):e1075113. eCollection 2016 Feb.

18.

Targeting inhibition of Foxp3 by a CD28 2'-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy.

Lozano T, Soldevilla MM, Casares N, Villanueva H, Bendandi M, Lasarte JJ, Pastor F.

Biomaterials. 2016 Jun;91:73-80. doi: 10.1016/j.biomaterials.2016.03.007. Epub 2016 Mar 8.

PMID:
26999456
19.

MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells.

Soldevilla MM, Villanueva H, Casares N, Lasarte JJ, Bendandi M, Inoges S, López-Díaz de Cerio A, Pastor F.

Oncotarget. 2016 Apr 26;7(17):23182-96. doi: 10.18632/oncotarget.8095.

20.

Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance.

Zabaleta A, Riezu-Boj JI, Larrea E, Villanueva L, Lasarte JJ, Guruceaga E, Fisicaro P, Ezzikouri S, Missale G, Ferrari C, Benjelloun S, Prieto J, Sarobe P.

J Med Virol. 2016 May;88(5):843-51. doi: 10.1002/jmv.24399. Epub 2015 Oct 19.

PMID:
26447929
21.

Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.

San Miguel JF, Paiva B, Lasarte JJ.

Cancer Cell. 2015 Sep 14;28(3):281-3. doi: 10.1016/j.ccell.2015.08.009. Review.

22.

Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.

Lozano T, Villanueva L, Durántez M, Gorraiz M, Ruiz M, Belsúe V, Riezu-Boj JI, Hervás-Stubbs S, Oyarzábal J, Bandukwala H, Lourenço AR, Coffer PJ, Sarobe P, Prieto J, Casares N, Lasarte JJ.

J Immunol. 2015 Oct 1;195(7):3180-9. doi: 10.4049/jimmunol.1402997. Epub 2015 Aug 31.

23.

Immune monitoring of immunosuppression withdrawal of liver transplant recipients.

García de la Garza R, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, Delgado JA, Silva L, Iñarrairaegui M, Sangro B, Sola I, Pardo F, Quiroga J, Ignacio Herrero J.

Transpl Immunol. 2015 Oct;33(2):110-6. doi: 10.1016/j.trim.2015.07.006. Epub 2015 Jul 29.

PMID:
26225458
24.

Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners.

Matsoukas MT, Aranguren-Ibáñez Á, Lozano T, Nunes V, Lasarte JJ, Pardo L, Pérez-Riba M.

Sci Signal. 2015 Jun 23;8(382):ra63. doi: 10.1126/scisignal.2005918.

PMID:
26106221
25.

Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.

Zabaleta A, D'Avola D, Echeverria I, Llopiz D, Silva L, Villanueva L, Riezu-Boj JI, Larrea E, Pereboev A, Lasarte JJ, Rodriguez-Lago I, Iñarrairaegui M, Sangro B, Prieto J, Sarobe P.

Mol Ther Methods Clin Dev. 2015 Mar 11;2:15006. doi: 10.1038/mtm.2015.6. eCollection 2015.

26.

Genetic basis for clinical response to CTLA-4 blockade.

Melero I, Lasarte JJ.

N Engl J Med. 2015 Feb 19;372(8):783. doi: 10.1056/NEJMc1415938. No abstract available.

PMID:
25693025
27.

Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L.

Llopiz D, Huarte E, Ruiz M, Bezunartea J, Belsúe V, Zabaleta A, Lasarte JJ, Prieto J, Borrás-Cuesta F, Sarobe P.

Oncoimmunology. 2013 Dec 1;2(12):e27009. Epub 2013 Dec 5.

28.

Searching for the Achilles Heel of FOXP3.

Lozano T, Casares N, Lasarte JJ.

Front Oncol. 2013 Dec 3;3:294. doi: 10.3389/fonc.2013.00294. Review.

29.

A fusion protein between streptavidin and the endogenous TLR4 ligand EDA targets biotinylated antigens to dendritic cells and induces T cell responses in vivo.

Arribillaga L, Durantez M, Lozano T, Rudilla F, Rehberger F, Casares N, Villanueva L, Martinez M, Gorraiz M, Borrás-Cuesta F, Sarobe P, Prieto J, Lasarte JJ.

Biomed Res Int. 2013;2013:864720. doi: 10.1155/2013/864720. Epub 2013 Sep 5.

30.

Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance.

de la Garza RG, Sarobe P, Merino J, Lasarte JJ, D'Avola D, Belsue V, Delgado JA, Silva L, Iñarrairaegui M, Sangro B, Sola JJ, Pardo F, Quiroga J, Herrero JI.

Liver Transpl. 2013 Sep;19(9):937-44. doi: 10.1002/lt.23686. Epub 2013 Jul 26.

31.

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J.

J Hepatol. 2013 Jul;59(1):81-8. doi: 10.1016/j.jhep.2013.02.022. Epub 2013 Mar 4.

PMID:
23466307
32.

Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R.

J Immunol. 2012 Nov 1;189(9):4674-83. doi: 10.4049/jimmunol.1201654. Epub 2012 Oct 1.

33.

The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice.

Román BS, Garrido V, Muñoz PM, Arribillaga L, García B, De Andrés X, Zabaleta V, Mansilla C, Farrán I, Lasa I, De Andrés D, Amorena B, Lasarte JJ, Grilló MJ.

Vet Res. 2012 Apr 19;43:31. doi: 10.1186/1297-9716-43-31.

34.

Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses.

Rudilla F, Fayolle C, Casares N, Durantez M, Arribillaga L, Lozano T, Villanueva L, Pio R, Sarobe P, Leclerc C, Prieto J, Lasarte JJ.

Vaccine. 2012 Apr 16;30(18):2848-58. doi: 10.1016/j.vaccine.2012.02.052. Epub 2012 Mar 2.

35.

The extradomain A of fibronectin (EDA) combined with poly(I:C) enhances the immune response to HIV-1 p24 protein and the protection against recombinant Listeria monocytogenes-Gag infection in the mouse model.

San Román B, De Andrés X, Muñoz PM, Obregón P, Asensio AC, Garrido V, Mansilla C, Arribillaga L, Lasarte JJ, De Andrés D, Amorena B, Grilló MJ.

Vaccine. 2012 Mar 28;30(15):2564-9. doi: 10.1016/j.vaccine.2012.01.081. Epub 2012 Feb 8.

PMID:
22326778
36.

Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin.

Mansilla C, Berraondo P, Durantez M, Martínez M, Casares N, Arribillaga L, Rudilla F, Fioravanti J, Lozano T, Villanueva L, Sarobe P, Borrás F, Leclerc C, Prieto J, Lasarte JJ.

Int J Cancer. 2012 Aug 1;131(3):641-51. doi: 10.1002/ijc.26412. Epub 2011 Oct 5.

37.

Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators.

Camacho AI, Da Costa Martins R, Tamayo I, de Souza J, Lasarte JJ, Mansilla C, Esparza I, Irache JM, Gamazo C.

Vaccine. 2011 Sep 22;29(41):7130-5. doi: 10.1016/j.vaccine.2011.05.072. Epub 2011 Jun 7.

38.

Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.

Echeverria I, Pereboev A, Silva L, Zabaleta A, Riezu-Boj JI, Bes M, Cubero M, Borras-Cuesta F, Lasarte JJ, Esteban JI, Prieto J, Sarobe P.

Hepatology. 2011 Jul;54(1):28-37. doi: 10.1002/hep.24325. Epub 2011 May 14.

39.

Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors.

Aranda F, Llopiz D, Díaz-Valdés N, Riezu-Boj JI, Bezunartea J, Ruiz M, Martínez M, Durantez M, Mansilla C, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Cancer Res. 2011 May 1;71(9):3214-24. doi: 10.1158/0008-5472.CAN-10-3259. Epub 2011 Mar 14.

40.

Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy.

Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, Boucontet L, Apetoh L, Ghiringhelli F, Casares N, Lasarte JJ, Matsuzaki G, Ikuta K, Ryffel B, Benlagha K, Tesnière A, Ibrahim N, Déchanet-Merville J, Chaput N, Smyth MJ, Kroemer G, Zitvogel L.

J Exp Med. 2011 Mar 14;208(3):491-503. doi: 10.1084/jem.20100269. Epub 2011 Mar 7. Erratum in: J Exp Med. 2011 Apr 11:208(4):869.

41.

Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis.

Arribillaga L, Dotor J, Basagoiti M, Riezu-Boj JI, Borrás-Cuesta F, Lasarte JJ, Sarobe P, Cornet ME, Feijoó E.

Cytokine. 2011 Mar;53(3):327-33. doi: 10.1016/j.cyto.2010.11.019. Epub 2010 Dec 23.

PMID:
21185199
42.

Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10.

Díaz-Valdés N, Manterola L, Belsúe V, Riezu-Boj JI, Larrea E, Echeverria I, Llópiz D, López-Sagaseta J, Lerat H, Pawlotsky JM, Prieto J, Lasarte JJ, Borrás-Cuesta F, Sarobe P.

Hepatology. 2011 Jan;53(1):23-31. doi: 10.1002/hep.23980. Epub 2010 Dec 13.

43.

Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection.

Riezu-Boj JI, Larrea E, Aldabe R, Guembe L, Casares N, Galeano E, Echeverria I, Sarobe P, Herrero I, Sangro B, Prieto J, Lasarte JJ.

J Hepatol. 2011 Mar;54(3):422-31. doi: 10.1016/j.jhep.2010.07.014. Epub 2010 Sep 26.

44.

A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice.

Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T, López-Sagaseta J, Guembe L, Sarobe P, Prieto J, Borrás-Cuesta F, Lasarte JJ.

J Immunol. 2010 Nov 1;185(9):5150-9. doi: 10.4049/jimmunol.1001114. Epub 2010 Sep 24.

45.

Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis.

Durantez M, Fayolle C, Casares N, Belsue V, Riezu-Boj JI, Sarobe P, Prieto J, Borrás-Cuesta F, Leclerc C, Lasarte JJ.

Vaccine. 2010 Oct 18;28(44):7146-54. doi: 10.1016/j.vaccine.2010.08.070. Epub 2010 Sep 15.

46.

Identification of CD4+ and CD8+ T cell epitopes of woodchuck hepatitis virus core and surface antigens in BALB/c mice.

Ochoa-Callejero L, Otano I, Vales A, Olagüe C, Sarobe P, Lasarte JJ, Prieto J, Menne S, González-Aseguinolaza G.

Vaccine. 2010 Jul 19;28(32):5323-31.

PMID:
20665977
47.

Dynamic of nasal colonization by methicillin-resistant Staphylococcus aureus ST398 and ST1 after mupirocin treatment in a family in close contact with pigs.

Lozano C, Aspiroz C, Lasarte JJ, Gómez-Sanz E, Zarazaga M, Torres C.

Comp Immunol Microbiol Infect Dis. 2011 Jan;34(1):e1-7. doi: 10.1016/j.cimid.2010.06.006.

PMID:
20663559
48.

Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation.

Tamayo I, Irache JM, Mansilla C, Ochoa-Repáraz J, Lasarte JJ, Gamazo C.

Clin Vaccine Immunol. 2010 Sep;17(9):1356-62. doi: 10.1128/CVI.00164-10. Epub 2010 Jul 14.

49.

The vaccine adjuvant extra domain A from fibronectin retains its proinflammatory properties when expressed in tobacco chloroplasts.

Farran I, McCarthy-Suárez I, Río-Manterola F, Mansilla C, Lasarte JJ, Mingo-Castel AM.

Planta. 2010 Mar;231(4):977-90. doi: 10.1007/s00425-010-1102-4. Epub 2010 Jan 28.

PMID:
20108000
50.

Skin lesion caused by ST398 and ST1 MRSA, Spain.

Aspiroz C, Lozano C, Vindel A, Lasarte JJ, Zarazaga M, Torres C.

Emerg Infect Dis. 2010 Jan;16(1):157-9. doi: 10.3201/eid1601.090694. No abstract available.

Supplemental Content

Loading ...
Support Center